Intravitreal aflibercept for diabetic macular oedema: Moorfields’ real-world 12-month visual acuity and anatomical outcomes by Lukic, M et al.
 1 
Intravitreal Aflibercept for Diabetic Macular Oedema; Moorfields’ Real-World 12 
Month Visual Acuity and Anatomical Outcomes  
 
 Dr Marko Lukic1, Mr Gwyn Williams1, Mr Zaid Shalchi1, Ms Dawn Sim1, Mr Praveen   
J. Patel1, Mr Pearse  A. Keane1, Mr Philip G. Hykin1, Prof Sobha Sivaprasad 1, Dr 
Deepthy Menon1, Dr Alice Bruynseels1, Mr Robin D. Hamilton1, Mr Ranjan 
Rajendram1 
 
Corresponding author:  Marko Lukic, MD FEBO 
Address: 162 City Road, EC1V 2 PD, London, UK                             
E-mail address: marko.lukic@moorfields.nhs.uk 
 
 




1   NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation 






To assess structural and functional outcomes of treatment with intravitreal aflibercept 
(® Eylea) for diabetic macular oedema (DMO) in treatment-naive patients. 
Design: This is a retrospective, real-life, cohort study. 
Participants and Methods:  
Ninety-two diabetic patients (102 eyes) receiving intravitreal anti-VEGF therapy were 
included. Ninety-nine aflibercept treated eyes were included in the statistical 
analysis. Each patient had corrected visual acuity in ETDRS letters and OCT central 
foveal thickness (CFT) and macular volume (MV) performed at baseline and 12 
months. Patients were initiated on a loading phase of five one-monthly intravitreal 
aflibercept injections, followed by injections if needed as per clinicians’ discretion. 
Results:  
The mean number of aflibercept injections received was 6.92. At baseline, the mean 
VA (SD) (Snellen) was 59.7 (16.1) (20/63) ETDRS letters, the mean CFT (SD) was 
431 (129) µm whilst the mean MV (SD) was 9.53 (1.79) mm3.  At 12 months, the 
mean VA (SD) (Snellen) was 69.6 (15.2) (20/40) ETDRS letters (p < .0001). Mean 
CFT (SD) was 306 (122) μm (p < .0001) and mean MV (SD) was 8.43 (1.58) mm3 (p 
< .0001) at 12 months. Thirty-three (33.67 %) eyes gained ≥ 15 ETDRS letters at 




Conclusions:   
There was a significant improvement in VA and in anatomical outcomes in 
aflibercept-treated eyes at 12 months after commencing treatment for DME in real 


















  Diabetic macular oedema (DMO) is a leading cause of visual loss in the working 
age population. (1)  It has been recognized that vascular endothelial growth factor 
(VEGF) is pivotal to the pathogenesis of DMO. (2,3) The modern approach to DMO 
treatment therefore relies on the proven safety and efficacy of intravitreal anti-VEGF 
drugs such as bevacizumab, ranibizumab and aflibercept, all of which have 
demonstrated functional and anatomical efficacy in clinical trials. (2-7) 
  Several large randomised controlled studies have established the efficacy of 
ranibizumab in diabetic macular oedema. The Diabetic Retinopathy Clinical 
Research (DRCR) network found ranibizumab with or without laser was significantly 
better than laser alone for visual acuity and anatomical outcomes. (8)  Around 30% 
of eyes in ranibizumab plus deferred laser arm had improvement of  15 ETDRS 
(Early Treatment Diabetic Retinopathy Study) letters in year 1. In addition, nearly 
50% of eyes of the same arm had improvement of   10 ETDRS letters. The RISE 
and RIDE studies showed ranibizumab is significantly more effective than sham for 
centre-involving DMO. (9) In the RISE and RIDE studies patients received monthly 
injections of ranibizumab. Our group recently published real-world outcomes of 
ranibizumab in DMO at our institution, showing comparable outcomes to these 
clinical trials. (10) 
  The VIVID and VISTA studies compared the safety and efficacy of intravitreal 
aflibercept to macular laser, finding a mean 10.7-12.5 letter gain in the aflibercept 
group compared to 0.2 letters in the laser group at 1 year. (11) The efficacy of 
aflibercept was further highlighted in DRCR Protocol T, in which aflibercept showed 
an advantage over ranibizumab at year 1, although there was no significant 
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difference between ranibizumab and aflibercept at year 2. (12) However, clinical 
trials select the most motivated of patients and have personnel to ensure efficient 
attendance and timely trial completion. Trials also have strict exclusion criteria such 
as very poor glycaemic control. We wanted to investigate the efficacy of intravitreal 
aflibercept for the treatment of centre-involving DMO in a real-world setting where 
“all-comers” are seen.  
METHODS 
   This retrospective cohort study included 102 eyes (of 92 diabetic patients) with 
centre-involving diabetic macular oedema ( 400 microns as per National Institute of 
Care and Excellence (NICE) criteria). This study entered only treatment naïve eyes 
which were funded for intravitreal aflibercept treatment for DMO between November 
2015 and May 2016. Patients older than 18 years of age with either diabetes mellitus 
(DM) type 1 or type 2 were included. All grades of diabetic retinopathy (DR) were 
included. DMO and DR were graded by using the modified Early Treatment Diabetic 
Retinopathy Study (ETDRS) classification system based on clinical appearance. 
HBA1c was recorded but did not influence treatment decisions at onset of treatment. 
Patients with hypertension, other comorbidities and patients with vitreoretinal 
conditions such as epiretinal membrane were not excluded. Each patient prior 
initiation of treatment had FFA and/or OCTA imaging done which is part of the 
Moorfields’ guidelines. We definied severe macular ischaemia using ETDRS criteria 
by using FAZ size, FAZ outline and capillary loss in central subfield. Patients who 
had FAZ greater than 1500 microns GLD in size, capillary outline completely 
destroyed and who had severe capillary loss were considered as severe macular 
ischaemia.  None of the patient had severe macular ischaemia or were excluded. 
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  The study was approved prospectively by the Clinical Audit and Assessment 
Committee of Moorfields Eye Hospital and registered with the trust clinical audit 
department (reference no: CA17/MR/06). Patients who had consented to imaging 
and anonymised data collection and analysis of outcomes as part of their clinical 
care were included and the study followed the tenets of the Declaration of Helsinki. 
All patients were under the care of Moorfields Eye Hospital (MEH) National Health 
Service (NHS) Trust, London, United Kingdom. 
  All eyes included in the study were treatment naïve at baseline and were treated 
with intravitreal aflibercept injections. Patients were initiated on a loading phase of 
five one-monthly intravitreal aflibercept injections, followed by injections if needed as 
per clinicians’ discretion. Clinical decision on further injections following the loading 
phase was on the basis of treating towards Visual Acuity and OCT scan stability i.e. 
if there was potential for further VA and/or OCT improvement (e.g. persistent fluid) 
after the loading phase, further injections were given.  Visual acuity (VA) 
measurements expressed in Early Treatment Diabetic Retinopathy Study (ETDRS) 
letters and Optical Coherence Tomography (OCT) (Topcon, Tokyo, Japan) scans 
were performed at each visit. 
  Primary outcomes were visual acuity (VA), central foveal thickness (CFT) and 
macular volume (MV) 12 months after commencing treatment. Secondary outcomes 
were percentage of eyes that achieved visual acuity gain of  10 and  15 ETDRS 
letters as well as percentage of eyes achieved reduction in CFT of 100 microns or 
more. Additionally, we carried out subgroup analysis according to the baseline VA 
(worse than 69 ETDRS letters or  69 ETDRS letters) and mean change in VA, CFT 
and MV at month 12.  
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  Key exclusion criteria included a history of an acute coronary event or 
cerebrovascular accident in the previous 3 months, pregnancy or lactation, active 
infection or intraocular inflammation in either eye, poor view of the fundus, severe 
macular ischaemia, other pathologies contributing towards macular oedema, anti-
VEGF treatment received for any other condition and other macular diseases 
present at baseline that might confound the outcomes such as a coexistent retinal 
vein occlusion.  
  We assessed the primary and secondary outcomes at 12 months. The t-paired 
sample test was used to determine statistical significance 
(https://www.graphpad.com/quickcalcs/ttest1.cfm) . A P value of <0.05 was 
interpreted as statistically significant.  
RESULTS 
  Ninety-nine aflibercept treated eyes (89 patients) entered the statistical analysis. 
Three eyes out of 102 were excluded as they were switched to other treatment over 
12 - month follow up period. The mean number of aflibercept injections received was 
6.92 (Figure 1). Fourteen percent of included eyes had less than 5 monthly loading 
doses (minimum 3) due to either clinicians’ discretion or patients did not attend or 
cancelled their appointments. Thirty percent of included eyes did not have further 
injections after the loading phase. Two patients (two eyes from the cohort) did not 
complete the follow up of 12 months. 33% of patients were pseudophakic and 67% 
were phakic at baseline. 
Aflibercept cohort outcomes  
At baseline, the mean VA (SD) (Snellen) was 59.7 (16.1) (20/63) ETDRS letters, the 
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mean CFT (SD) was 431 (129) µm whilst the mean MV (SD) was 9.53 (1.79) mm3. 
(Table 1) At 12 months, the mean VA (SD) (Snellen) was 69.6 (15.2) (20/40) ETDRS 
letters (p < .0001).  The mean CFT (SD) was 306 (122) μm (p < .0001) and the mean 
MV (SD) was 8.43 (1.58) mm3 (p < .0001) at 12 months. Thirty-three (33.67 %) eyes 
gained ≥ 15 ETDRS letters at month 12, and 50 (55.55%) eyes had a decrease in 
CFT of ≥ 100 microns (Table 2). Three (3.06 %) eyes lost ≥ 15 ETDRS letters and 6 
(6.66 %) eyes had an increase in CFT of ≥ 100 microns at the end of follow up 
period. Forty-seven (46.53%) eyes achieved 10 ETDRS letters or more gain at 
month 12, whilst 5 (4.95%) eyes lost 10 ETDRS letters or more at the end of follow 
up.  
Mean changes and sub-group analysis according to baseline VA and CFT 
  We calculated the changes in VA, CFT and MV after 12 months. The mean change 
in VA was + 9.9 ETDRS.  The mean change in MV was -1.08 mm3 whilst the mean 
change in the CFT was -128 μm. 
  We sub-divided the included eyes into two subgroups according to the baseline 
visual acuity; < 69 ETDRS letters (< 20/50 Snellen) and  69 ETDRS letters ( 20/40 
Snellen) and according to the baseline CFT; 400- 499 microns or   500 microns. 
Sixty-six percent of eyes had baseline visual acuity less than 69 ETDRS letters (< 
20/50 Snellen). The mean change in visual acuity in the subgroup with baseline VA 
less than 69 letters (< 20/50 Snellen) was +13.8 ETDRS letters (Figure 2). Thirty-four 
percent of eyes had baseline visual acuity  69 ETDRS letters ( 20/40 Snellen) and 
the mean change in the visual acuity after 12 months in that subgroup was + 2.6 
ETDRS letters. The subgroup of eyes with initially worse visual acuity (< 20/50 
Snellen) had mean 7.4 intravitreal injections of aflibercept over 12 months whilst the 
 9 
subgroup with initial visual acuity of  20/40 Snellen had mean 6.6 injections over 
same follow up period (p = .07) Twenty-seven percent of included eyes had baseline 
CFT of 500 microns or more. The mean change in CFT in that subgroup was -265 
microns. In the subgroup where the baseline CFT was between 500 and 400 
microns the mean change in CFT was -86 microns. 
DISCUSSION 
  Clinical trials generally produce results above what would be expected to occur in a 
normal patient population, with real world evidence rarely indicating equivalence. 
There are myriad reasons for this, including tight inclusion and exclusion criteria, a 
well-motivated patient population, more injections given and a mandated tight 
appointment schedule. The DRCR.net Protocol T study demonstrated a 13.3 letter 
gain with aflibercept therapy, with the mean VA at baseline being 64.8 ETDRS 
letters. (12) The major trials examining anti-VEGF effect in DMO (VIVID, VISTA, 
RESOLVE, RESTORE, RISE, RIDE, RETAIN, Da VINCI) had a baseline VA that 
ranged from 56.9 letters to 64.8 ETDRS letters with VA gain ranging from 6.8 to 13.1 
letters over the first year of the study.(13-16) An inverse correlation was noted 
whereby patients with the higher baseline VA demonstrated the lower improvement 
in acuity.  
  Real-world results have not displayed the same amount of improvement in visual 
acuity with anti VEGF treatment in DMO, with the frequency of injections being the 
factor that tends to be cited in order to explain this finding. (17) There are no large-
scale real-world data looking at aflibercept therapy for DMO. However, it was 
previously hypothesised based on diminished number of injections in a real world 
setting that the results would be inferior to the major trials. Our study is look at real 
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world evidence of aflibercept use and with an average of 6.92 injections, significantly 
less than the 9-10 observed in DRCR.net protocol T, with around 10 ETDRS letters 
of improvement noted. In those eyes with VA of less than 69 letters, the 
improvement in acuity was markedly greater than in those with higher baseline visual 
acuity scores, thus confirming the ceiling effect seen when treating patients with 
good initial baseline acuity. The ceiling effect was noted when divided our cohort 
based on degree of foveal thickening. Our results indicate that despite a significantly 
lower number of injections over a 12-month period than those observed in the 
landmark trials, good visual and anatomical outcomes are attainable. 
   The number of injections was less than those used in the large clinical studies. We 
believe this is a significant collection of real-world outcomes that show very good 
results with aflibercept therapy for diabetic macular oedema in a real-world setting.     
Regardless to the  limitations of this study, which  are number of patients included, 
and lack of more detailed analysis of macular perfusion, we believe that the reporting 
of real-world outcomes is of benefit to clinicians who are treating patients in the real 
world, rather than a clinic trial setting and thus do not see this as a limitation. 
  Real world evidence is important in making decisions about how to treat patients 
with DMO in an efficient and cost-effective manner. Modern healthcare systems may 
not be able to provide injections at the same frequency for sustained periods of time 
as was observed in the major studies. This is the largest published dataset 
examining aflibercept therapy provided in a real world setting and our observed 
improvement could potentially be explained in theory by the pharmacokinetic 
advantages of aflibercept in its increased binding affinity for VEGF, its longer 
duration of action and ability to bind placental growth factor. Whatever the reason we 
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have demonstrated that it is possible to deliver very good visual acuity and 
anatomical outcomes in a real-world setting using less injections than those used in 
the published literature. Diabetic maculopathy is a major cause of sight impairment 
amongst working age people and the prevalence of type 2 diabetes is rapidly 
increasing in both the developed and less well-developed world economies. We 
demonstrate that good outcomes can be achieved in the real world away from 
clinical trials and this should support doctors and patients together in managing 
diabetic macular oedema. 
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Figure 1. Number of eyes per number of injections of the cohort in 12 months follow-
up 
 
Figure 2. Visual acuity change over 12 months in the main cohort and two subgroups 
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Table 1    Aflibercept cohort:  General data;  CFT = Central Foveal Thickness,  MV = Macular      
Volume,  SD = Standard Deviation,  VA = Visual Acuity 
 AFLIBERCEPT COHORT 
TREATED EYES 99 
MEAN VA  BASELINE (SD)     (Snellen) ETDRS letters 59.66 (16.11) (20/63) 
MEAN VA  5 MONTHS (SD)    (Snellen) ETDRS letters 66.5 (13.65) (20/40) 
MEAN VA 12 MONTHS  (SD)  (Snellen) ETDRS letters  [p value] 
 
69.56 (15.24) (20/40)   [p < .0001] 
MEAN VA CHANGE  ETDRS letters 
 
+ 9.9 
MEAN CFT BASELINE (SD)   microns 
 
431 (129) 
MEAN CFT  5 MONTHS  (SD)  microns 
 
298 (101) 
MEAN CFT  12 MONTHS  (SD)  microns [ p value] 
 
306 (122)  [p < .0001] 
MEAN CFT CHANGE   microns 
 
-128 
MEAN MV  BASELINE (SD)   mm3 
 
9.53 (1.79) 
MEAN MV 5 MONTHS  (SD)   mm3 
 
8.5 (2.03) 
MEAN MV 12 MONTHS  (SD)   mm3  [p value] 
 
8.43 (1.58) [p < .0001] 
MEAN MV CHANGE   mm3 
 
-1.08 
MEAN NUMBER OF INJECTIONS 6.92 
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Table 2   Changes in VA and CFT; CFT = Central Foveal Thickness,  MV = Macular Volume,  SD = 




























VA COHORT  (eyes) 
 
% 
≥ 15 letters gain  33 33.67 % 
< 15 letters gain  47 47.95 % 
≥ 15 letters loss  3 3.06 % 
< 15 letters loss  15 15.30 % 
 









≥  - 100 microns 50 50.50 % 
< - 100 microns 21 21.21 % 
    ≥  100 microns 6 6.06 % 
    <  100 microns 13 13.13 % 
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Table 3   Macular oedema appearance at baseline; DMO = Diabetic Macular Oedema,  CSMO = 
Clinically Significant Macular Oedema 




DIFFUSE CSMO, INVOLVING 
FOVEA 
64 
FOCAL CSMO, INVOLVING 
FOVEA 
7 
PRESENCE OF SUBRETINAL 
FLUID 
18 
PRESENCE OF EPIRETINAL 
MEMBRANE  
13 
VITREO-MACULAR 
TRACTION 
2 
 
